Hannah Johnson Roberts, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Chemoembolization, Therapeutic | 1 | 2021 | 128 | 0.720 |
Why?
|
X-Ray Therapy | 1 | 2016 | 8 | 0.560 |
Why?
|
Paintings | 1 | 2016 | 103 | 0.490 |
Why?
|
Radiosurgery | 2 | 2022 | 1342 | 0.420 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2022 | 2298 | 0.400 |
Why?
|
Radiation Oncology | 1 | 2016 | 563 | 0.350 |
Why?
|
Liver Neoplasms | 2 | 2022 | 4320 | 0.320 |
Why?
|
Rectal Neoplasms | 2 | 2024 | 1157 | 0.240 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2024 | 1726 | 0.210 |
Why?
|
Pancreatic Neoplasms | 3 | 2024 | 5365 | 0.200 |
Why?
|
Lymphopenia | 1 | 2024 | 280 | 0.200 |
Why?
|
Students, Medical | 1 | 2015 | 1930 | 0.200 |
Why?
|
Curriculum | 1 | 2015 | 3741 | 0.190 |
Why?
|
Collagen Type I | 1 | 2024 | 616 | 0.190 |
Why?
|
Dementia | 1 | 2015 | 2686 | 0.180 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 4014 | 0.180 |
Why?
|
Neoadjuvant Therapy | 4 | 2024 | 2826 | 0.180 |
Why?
|
Cholangiocarcinoma | 1 | 2024 | 552 | 0.160 |
Why?
|
Bile Duct Neoplasms | 1 | 2024 | 605 | 0.160 |
Why?
|
Posters as Topic | 1 | 2016 | 6 | 0.140 |
Why?
|
Folklore | 1 | 2016 | 7 | 0.140 |
Why?
|
Medicine in Literature | 1 | 2016 | 32 | 0.130 |
Why?
|
Radium | 1 | 2016 | 72 | 0.130 |
Why?
|
Urothelium | 1 | 2016 | 269 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1051 | 0.120 |
Why?
|
Feasibility Studies | 1 | 2023 | 5246 | 0.100 |
Why?
|
Neoplasm Staging | 2 | 2024 | 11106 | 0.100 |
Why?
|
Cystectomy | 1 | 2016 | 634 | 0.100 |
Why?
|
Leucovorin | 2 | 2024 | 642 | 0.100 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3874 | 0.090 |
Why?
|
Fluorouracil | 2 | 2024 | 1639 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11740 | 0.080 |
Why?
|
History, 20th Century | 1 | 2016 | 2769 | 0.080 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6485 | 0.080 |
Why?
|
Carcinoma | 1 | 2016 | 2330 | 0.060 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2016 | 2223 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5302 | 0.060 |
Why?
|
Gallium Radioisotopes | 1 | 2024 | 195 | 0.060 |
Why?
|
Retrospective Studies | 4 | 2024 | 80582 | 0.050 |
Why?
|
Humans | 12 | 2024 | 761423 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2024 | 1784 | 0.040 |
Why?
|
Pancreatectomy | 1 | 2023 | 811 | 0.040 |
Why?
|
Mice, Nude | 1 | 2024 | 3614 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13337 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 16979 | 0.040 |
Why?
|
Fibrosis | 1 | 2024 | 2048 | 0.040 |
Why?
|
Cell Communication | 1 | 2024 | 1657 | 0.040 |
Why?
|
Prospective Studies | 1 | 2021 | 54415 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36423 | 0.030 |
Why?
|
Propensity Score | 1 | 2023 | 1908 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2024 | 64651 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2024 | 2651 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2024 | 3207 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2449 | 0.030 |
Why?
|
Prognosis | 2 | 2024 | 29620 | 0.030 |
Why?
|
Male | 5 | 2024 | 360736 | 0.020 |
Why?
|
Adult | 3 | 2024 | 221148 | 0.020 |
Why?
|
Survival Rate | 1 | 2024 | 12720 | 0.020 |
Why?
|
Aged | 4 | 2024 | 169235 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5305 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3589 | 0.020 |
Why?
|
Young Adult | 1 | 2015 | 59207 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2024 | 58956 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9418 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2024 | 8545 | 0.020 |
Why?
|
Middle Aged | 4 | 2024 | 220826 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2578 | 0.020 |
Why?
|
Female | 4 | 2024 | 392581 | 0.020 |
Why?
|
Neoplasms | 1 | 2016 | 22164 | 0.020 |
Why?
|
Age Factors | 1 | 2023 | 18400 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6814 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6479 | 0.020 |
Why?
|
Liver | 1 | 2022 | 7532 | 0.020 |
Why?
|
Boston | 1 | 2016 | 9330 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12058 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2024 | 39117 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12456 | 0.010 |
Why?
|
Algorithms | 1 | 2022 | 14026 | 0.010 |
Why?
|
Signal Transduction | 1 | 2024 | 23441 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 23990 | 0.010 |
Why?
|
Disease Progression | 1 | 2016 | 13502 | 0.010 |
Why?
|
Mice | 1 | 2024 | 81509 | 0.010 |
Why?
|
Time Factors | 1 | 2016 | 39975 | 0.010 |
Why?
|
United States | 1 | 2022 | 72339 | 0.010 |
Why?
|
Animals | 1 | 2024 | 168441 | 0.010 |
Why?
|
Risk Factors | 1 | 2016 | 74167 | 0.010 |
Why?
|